Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liv...(ed to the followingstatements: Raptor's ...),Health

Date:7/16/2008

ed to the following statements: Raptor's ability to develop DR Cysteamine to improve bioavailability, reduce side effects and reduce dosage frequency; Raptor's ability to develop DR Cysteamine for the treatment of Cystinosis; Raptor's ability to develop an appropriate dosage form of DR Cysteamine for NASH patients; and Raptor's ability to formulate and manufacture DR Cysteamine in clinical quantities to support clinical trials. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause our actual results to be materially different from these forward-looking statements. Factors which may significantly change or prevent our forward looking statements from fruition include that we may be unsuccessful in developing any products or acquiring products; that our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; that we are unable to retain or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able to raise sufficient funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in our filings from time to time with the Securities and Exchange Commission (the "SEC"), which we strongly urge you to read and consider, including our Registration Statem
'/>"/>

SOURCE Raptor Pharmaceuticals Corp. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
2. Raptor Pharmaceuticals Provides Update of Product Programs
3. MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion
4. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
5. MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
6. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial
7. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
10. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
11. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer